MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

52.608

87.826

EPS

0.4

Dividendrendement

0.29

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.66% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.26%

Volgende Winsten

30 jan 2026

Volgende dividenddatum

6 feb 2026

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

569M

12B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

30%

70%

91 / 372 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jan 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8 jan 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8 jan 2026, 20:54 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks -- Update

8 jan 2026, 20:44 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks

8 jan 2026, 17:05 UTC

Acquisities, Fusies, Overnames

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8 jan 2026, 16:43 UTC

Belangrijke Marktbewegers

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 jan 2026, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8 jan 2026, 22:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jan 2026, 22:42 UTC

Marktinformatie

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8 jan 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8 jan 2026, 21:53 UTC

Winsten

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 jan 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8 jan 2026, 21:09 UTC

Marktinformatie

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8 jan 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8 jan 2026, 20:21 UTC

Marktinformatie

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8 jan 2026, 19:44 UTC

Marktinformatie

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8 jan 2026, 18:50 UTC

Marktinformatie

Mexico's Industrial Production Seen Lower in November -- Market Talk

8 jan 2026, 17:48 UTC

Winsten

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jan 2026, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

8 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jan 2026, 16:45 UTC

Marktinformatie

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8 jan 2026, 16:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jan 2026, 16:03 UTC

Marktinformatie

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8 jan 2026, 16:02 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8 jan 2026, 15:23 UTC

Acquisities, Fusies, Overnames

Paramount Defends Its Hostile Bid for Warner -- Update

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

7.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 110.88 USD  7.66%

Hoogste 123 USD

Laagste 100 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

6

Buy

5

Hold

0

Sell

Sentiment

By Acuity

91 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat